Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1294228 | 0.84 | TDP1 (0.45) | CRHBPCRHR2TDP1KDM4EBACE1 | |
| SCHEMBL2416918 | 0.75 | BACE1 (0.49) | KDM4EBACE1 | |
| SCHEMBL12446257 | 0.73 | SLC40A1 (0.34) | CRHBPCRHR2 | |
| SCHEMBL20671158 | 0.70 | CYP1A2 (0.46) | CRHBPCRHR2TDP1KDM4E | |
| SCHEMBL31153402 | 0.70 | CYP1A2 (0.46) | CRHBPCRHR2TDP1KDM4E | |
| SCHEMBL17442941 | 0.70 | S1PR4 (0.35) | CRHBPCRHR2TDP1 | |
| SCHEMBL8396854 | 0.70 | HTR3A (0.45) | BACE1 | |
| SCHEMBL20660682 | 0.70 | NT5E (0.44) | CRHBPCRHR2TDP1KDM4EBACE1 | |
| SCHEMBL755383 | 0.70 | BACE1 (0.64) | KDM4EBACE1 | |
| SCHEMBL115958 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| CN-119954801-A | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-114867727-B | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2023125812-A1 | SUBSTITUTED PYRIMIDONE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | 上海海雁医药科技有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-20220315575-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-10-06 | — | — | US | disclosed |
| CN-114867727-A | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| EP-3999182-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20210283277-A1 | TAU PET IMAGING LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-16 | — | — | US | disclosed |
| US-20190038784-A1 | TAU PET IMAGING LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-07 | — | — | US | disclosed |
| WO-2017134098-A1 | TAU PET IMAGING LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315575-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | VHL, CRBN, MAPT | CRHBP 695/4885CRHR2 3367/4885TDP1 682/4885 |
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | CRHBP 650/4885CRHR2 3377/4885TDP1 892/4885 |
| US-20190038784-A1 | TAU PET IMAGING LIGANDS | MAPT, PSEN1, APP | CRHBP 1217/4885CRHR2 2987/4885TDP1 310/4885 |
| US-20210283277-A1 | TAU PET IMAGING LIGANDS | MAPT, PSEN1, APP | CRHBP 1217/4885CRHR2 2987/4885TDP1 310/4885 |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | VHL, CRBN, MAPT | CRHBP 695/4885CRHR2 3367/4885TDP1 682/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | CRHBP 750/4885CRHR2 2147/4885TDP1 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.